13 Nov 2019 07:00
13 November 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Directorate Change
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has decided to streamline its Board of Directors by limiting the Executive Officers on the Board to only the CEO and CFO, reducing its size from eight members to six.
Lou Ruggiero, Chief Business Officer, and Tom Hyland, Chief Operating Officer, will resign from the Company Board of Directors. Mr. Ruggiero's role with the Company will remain unchanged. Mr. Hyland will transition to a Chief Technical Adviser role in a consulting capacity and the Company does not plan to backfill the Chief Operating Officer position.
Chris Brinsmead, Chairman of Collagen Solutions, commented: "As the Company is preparing for its next stage of growth the time is right to adjust to a slimmer, more efficient executive team and Board. The executive team is highly focused on upgrading our production capabilities, strengthening our technical excellence, and organising the Company around meeting the growing demand for biomaterials product supply, development and contract manufacturing. By streamlining the Board, this enables the executive team to focus on these critical activities, whilst ensuring effective and efficient governance and support of the Board."
Collagen Solutions Plc |
| |||
Jamal Rushdy, CEO | Via Walbrook | |||
Hilary Spence, CFO |
| |||
|
| |||
Cenkos Securities Plc (Nominated Adviser and Broker) |
| |||
Giles Balleny (Corporate Finance) | Tel: 0207 397 8900 | |||
Stephen Keys |
| |||
|
| |||
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | |||
Anna Dunphy | Mob: 07876 741 001 | |||
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com